Merrimack Pharmaceuticals

3 results found.

Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosar Clinical Trial using MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Merrimack Pharmaceuticals - Recruiting 12 Months to 20 years.
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors.
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junc Clinical Trial using MM-111; Paclitaxel; Trastuzumab

Merrimack Pharmaceuticals - Recruiting 18 years or older.
- Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy.
MM-111; Paclitaxel; Trastuzumab

Breast Cancer Clinical Trial using MM-302 Monotherapy; MM-302 in combination with trastuzumab; MM-302 in combination with trastuzumab q3w; MM-302 in combination with trastuzumab and cyclophosphamide

Merrimack Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer.
MM-302 Monotherapy; MM-302 in combination with trastuzumab; MM-302 in combination with trastuzumab q3w; MM-302 in combination with trastuzumab and cyclophosphamide